Get the Stockscreener App
4.76
1.65%
-0.08
After Hours:
4.80
0.04
+0.84%
Precigen Inc stock is traded at $4.76, with a volume of 4.83M.
It is down -1.65% in the last 24 hours and up +16.95% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$4.84
Open:
$4.9
24h Volume:
4.83M
Relative Volume:
1.07
Market Cap:
$1.68B
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-12.21
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
+7.94%
1M Performance:
+16.95%
6M Performance:
+186.75%
1Y Performance:
+255.22%
1-Day Range:
$4.5944
$5.10
1-Week Range:
$4.20
$5.10
52-Week Range:
$1.11
$5.225
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.76 | 1.71B | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Strong Sell - MarketBeat
Market Pulse: Is Precigen Inc stock influenced by commodity pricesJuly 2025 Setups & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next - simplywall.st
Patient Capital Management LLC Grows Stake in Precigen, Inc. $PGEN - MarketBeat
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - Finviz
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Precigen, Inc. (NASDAQ:PGEN) Sees Large Growth in Short Interest - MarketBeat
Earnings Risk: Is Precigen Inc stock influenced by commodity prices2025 Price Targets & Low Volatility Stock Recommendations - baoquankhu1.vn
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone - Sahm
Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy? - simplywall.st
Precigen reports strong adoption of RRP treatment PAPZIMEOS By Investing.com - Investing.com Nigeria
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Precigen (NASDAQ:PGEN) Trading Down 7.5%What's Next? - MarketBeat
Precigen reports strong adoption of RRP treatment PAPZIMEOS - Investing.com
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Iridian Asset Management LLC CT Sells 611,716 Shares of Precigen, Inc. $PGEN - MarketBeat
Is Precigen Inc. stock a buy on dipsInsider Buying & Technical Analysis for Trade Confirmation - ulpravda.ru
Precigen, Inc. (PGEN) Stock Analysis: Biotechnology Innovator With Potential 84% Upside - DirectorsTalk Interviews
Can Precigen Inc. stock beat market expectations this quarterJuly 2025 Review & Fast Moving Stock Trade Plans - ulpravda.ru
Can Precigen Inc. stock double in next 5 yearsMarket Weekly Review & Fast Exit and Entry Strategy Plans - ulpravda.ru
Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic? - simplywall.st
Market Sentiment Around Loss-Making Precigen, Inc. (NASDAQ:PGEN) - 富途牛牛
Is Precigen Inc. stock a buy before product launchesMorning Star Patterns & Start Small. End Wealthy. - ulpravda.ru
Will Precigen Inc. stock recover faster than peersGeopolitical Risk Analysis & Amplify Gains With Picks - ulpravda.ru
Will Precigen Inc. stock see insider buying2026 world cup usa national team quarterfinals star players possession football tactical prediction insights - ulpravda.ru
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Co - GuruFocus
Precigen (NASDAQ:PGEN) Trading Down 6.1%What's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Trading Down 4.2%Here's What Happened - MarketBeat
Will PGEN’s New Drug Make a Splash? - StocksToTrade
Precigen (NASDAQ:PGEN) Shares Up 5.1%What's Next? - MarketBeat
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - Benzinga
Precigen (NASDAQ:PGEN) Shares Gap Down Following Insider Selling - MarketBeat
Monday’s Insider Activity: Andreessen Horowitz Leads Major Buys - Investing.com
Monday’s Insider Activity: Andreessen Horowitz Leads Major Buys By Investing.com - Investing.com UK
Precigen Insider Sold Shares Worth $7,942,150, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Precigen (NASDAQ:PGEN) Director Sells 1,900,036 Shares of Stock - MarketBeat
Kirk sells Precigen shares worth $7.9 million By Investing.com - Investing.com South Africa
Kirk sells Precigen shares worth $7.9 million - Investing.com
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Profit Review: Will Precigen Inc. stock see insider buyingInsider Selling & Real-Time Buy Signal Alerts - Улправда
Market Outlook: Is Precigen Inc. stock a buy on dipsWeekly Profit Report & Real-Time Volume Analysis - ulpravda.ru
Precigen, Inc. (PGEN) Stock Analysis: Exploring a 103.84% Upside Potential in the Booming Biotech Sector - DirectorsTalk Interviews
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st
PRECIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased - PR Newswire
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):